The Cochrane study concluded that the rates of symptomatic, overall and nocturnal hypoglycaemia were statistically significantly lower in patients treated with IDet or IGlar than those treated with NPH insulin 29, showing the progressive reduction of the risk of hypoglycaemia from NPH insulin to IGlar and IDet—a progression that will be continued with IDeg. The gene discussed is INS; the disease is Hypoglycemia.